We propose this work as a strategic reference for optimizing siRNA-tumor adaptive drug design, overcoming target innovation deficits (e.g., CSF2 homogeneity) and delivery limitations, thereby accelerating clinical translation of this drug class. The gene discussed is CSF2; the disease is neoplasm.